Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (Nasdaq:NKTR) announced that Phase 2b data for rezpegaldesleukin will be presented orally at the 2026 American Academy of Dermatology Annual Meeting, March 27-31, 2026, in Denver.
Two presentations on March 28 cover 36-week efficacy and safety in severe-to-very-severe alopecia areata and severity-dependent results in moderate-to-severe atopic dermatitis.
Nektar Therapeutics (Nasdaq: NKTR) reported Q4 and full-year 2025 results on March 12, 2026. Cash and investments were $245.8M at Dec 31, 2025, excluding ~$432M net proceeds from a Feb 2026 secondary and $44M from ATM sales.
Revenue fell to $55.2M in 2025 from $98.4M in 2024; 2025 net loss was $164.1M or $9.73 per share. Rezpegaldesleukin Phase 2 data supported a planned Phase 3 start in June 2026.
Nektar Therapeutics (NASDAQ:NKTR) announced inducement grants under its 2025 Inducement Plan on February 20, 2026. The Organization and Compensation Committee granted non-qualified stock options for a total of 4,300 shares to three newly hired employees with an exercise price of $73.73 per share.
The options carry an eight-year term and vest over four years (1/4 on the one-year anniversary, then monthly 1/48th for three years), subject to continued employment and the plan and option agreement terms.
Nektar (Nasdaq: NKTR) will announce fourth-quarter and year-ended December 31, 2025 financial results on Thursday, March 12, 2026 after U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT.
A live audio-only webcast and the press release will be available on the company’s Investors page. The webcast replay is available through April 12, 2026. Attendees must pre-register to receive dial-in details and a PIN for the live call.
Nektar Therapeutics (Nasdaq: NKTR) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston (March 2-4) and Jefferies Biotech on the Beach Summit in Miami (March 9-11).
The TD Cowen presentation is webcast on Wednesday, March 4, 2026 at 9:10 a.m. ET with a replay available for 30 days; one-on-one meetings at Jefferies are available by request.
Nektar Therapeutics (Nasdaq: NKTR) announced a research collaboration with UCSF and Dr. Stephen L. Hauser to study NKTR-0165, a first-in-class TNFR2 agonist antibody, in multiple sclerosis models. UCSF will conduct and fund the research; Nektar will supply NKTR-0165 and retain program rights.
The work will test TNFR2 agonism for neuroprotection, reduced neurodegeneration, and cell repair in neuron exposures to patient-derived B cells.
Nektar Therapeutics (Nasdaq: NKTR) closed an underwritten public offering that generated approximately $460 million in gross proceeds on Feb 13, 2026. The company sold 7,637,931 shares (including 1,034,482 shares from full exercise of the underwriters' option) and 293,103 pre-funded warrants.
Shares were priced at $58.00 per share and pre-funded warrants at $57.9999, before underwriting discounts, commissions and offering expenses. Jefferies, TD Cowen and Piper Sandler led the deal.
Nektar Therapeutics (Nasdaq: NKTR) priced an upsized public offering to raise approximately $400 million by selling 6,603,449 common shares and 293,103 pre-funded warrants at $58.00 (or $57.9999 for warrants) per unit.
The offering may close on February 13, 2026, includes a 30-day underwriter option for up to 1,034,482 additional shares, and intends net proceeds for general corporate purposes, including Phase 3 rezpegaldesleukin development and manufacturing.
Nektar Therapeutics (Nasdaq: NKTR) on Feb. 10, 2026 announced a proposed underwritten public offering of $300,000,000 of common stock and, for certain investors, pre-funded warrants, with a 30-day option for up to an additional $45,000,000. The offering is subject to market conditions.
Proceeds are intended for general corporate purposes, including research and development, clinical development (including Phase 3 trials for rezpegaldesleukin), and manufacturing. Jefferies, TD Cowen, and Piper Sandler are joint bookrunning managers. The securities will be offered under a Form S-3ASR shelf registration that became effective Nov. 12, 2025.
Nektar Therapeutics (Nasdaq: NKTR) reported 36-week blinded maintenance results from the 52-week REZOLVE-AD Phase 2b study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Key findings: durable EASI-75/EASI-90 and vIGA-AD 0/1 maintenance with 24 µg/kg Q4W and Q12W, up to 5-fold increases in EASI-100 during maintenance, favorable safety with 3.5% discontinuation for adverse events, and plan to advance to Phase 3 with a target BLA submission in 2029.